Aadi Biosciences
Clinical Trials
11
Trial Phases
2 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
- Conditions
- CancerTumorEndometrioid TumorEndometrial CancerRecurrent Endometrial CarcinomaEndometrioid Endometrial Cancer
- Interventions
- Drug: nab-sirolimus
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Aadi Bioscience, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05997017
- Locations
- 🇺🇸
Michael Birrer, MD, PhD, Little Rock, Arkansas, United States
🇺🇸Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
🇺🇸Women's Cancer Center of Nevada, Las Vegas, Nevada, United States
Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
- Conditions
- Neuroendocrine TumorsPancreatic Neuroendocrine TumorPulmonary Neuroendocrine TumorNETGastrointestinal Neuroendocrine Tumor
- Interventions
- Drug: nab-sirolimus
- First Posted Date
- 2023-08-18
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- Aadi Bioscience, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT05997056
- Locations
- 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment
- Conditions
- Tumor, SolidTumorAdvanced Solid Tumor
- Interventions
- Drug: nab-sirolimus
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Aadi Bioscience, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05661461
- Locations
- 🇺🇸
South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
- Conditions
- NeoplasmsTSC1Malignant Solid TumorMalignant Solid NeoplasmCancer MetastaticSolid TumorMalignant NeoplasmTumorTumor, SolidMetastasis
- Interventions
- Drug: nab-sirolimus
- First Posted Date
- 2021-11-02
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Aadi Bioscience, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05103358
- Locations
- 🇺🇸
Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Southern Cancer Center, Mobile, Alabama, United States
🇺🇸Arizona Oncology Associates, Irving, Texas, United States
Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation
- Conditions
- PEComa, MalignantTSC1TSC2mTOR Pathway Abberation
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Aadi Bioscience, Inc.
- Registration Number
- NCT03817515
- Prev
- 1
- 2
- 3
- Next
News
Nab-Sirolimus Demonstrates Promising Outcomes in Advanced PEComa Treatment
• Nab-sirolimus (Fyarro) has gained FDA approval for advanced malignant perivascular epithelioid cell tumors (PEComa), offering a new treatment option for this rare cancer. • The AMPECT trial demonstrated a 39% objective response rate, a median progression-free survival of 10.6 months, and an overall survival of 53.1 months with nab-sirolimus. • Unlike some therapies, nab-sirolimus does not require biomarker testing for treatment eligibility, expanding access for patients with PEComa. • The agent shows a favorable safety profile, with most adverse events being mild and manageable, leading to low discontinuation rates.